MaxCyte Signed A Partnership With Prime Medicine, Granting Non-Exclusive Clinical, Commercial Rights To Use MaxCyte's Flow Electroporation Technology, ExPERT Platform; In Return, MaxCyte Is Entitled To Receive Annual License Fees, Program-Related Revenue
Portfolio Pulse from Benzinga Newsdesk
MaxCyte has entered into a partnership with Prime Medicine, granting non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation Technology, ExPERT platform. In return, MaxCyte will receive annual license fees and program-related revenue.
August 01, 2023 | 12:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The partnership with Prime Medicine could increase MaxCyte's revenues through annual license fees and program-related revenue.
The partnership grants Prime Medicine non-exclusive rights to use MaxCyte's technology. This will generate annual license fees and program-related revenue for MaxCyte, potentially increasing its revenues and positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100